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ABSTRACT
Objective To explore a possible link between authors’
financial conflicts of interest and their position on the
association of rosiglitazone with increased risk of
myocardial infarction in patients with diabetes.
Data sources On 10 April 2009, we searched Web of
ScienceandScopusforarticlescitingandcommentingon
either oftwo indexpublications thatcontributedkeydata
to the controversy (a meta-analysis of small trials and a
subsequent large trial).
Data selection Articles had to comment on rosiglitazone
and the risk of myocardial infarction. Guidelines, meta-
analyses, reviews, clinical trials, letters, commentaries,
and editorials were included.
Data extraction For each article, we sought information
about the authors’ financial conflicts of interest in the
report itself and elsewhere (that is, in all publications
within two years of the original publication and online).
Two reviewers blinded to the authors’ financial
relationships independently classified each article as
presenting a favourable (that is, rosiglitazone does not
increase the risk of myocardial infarction), neutral, or
unfavourable view on the risk of myocardial infarction
withrosiglitazoneandonrecommendationsontheuseof
the drug.
Results Of the 202 included articles, 108 (53%) had a
conflict of interest statement. Ninety authors (45%) had
financial conflicts of interest. Authors who had a
favourable view of the risk of myocardial infarction with
rosiglitazone were more likely to have financial conflicts
of interest with manufacturers of antihyperglycaemic
agentsingeneral,andwithrosiglitazonemanufacturersin
particular, than authors who had an unfavourable view
(rate ratio 3.38, 95% CI 2.26 to 5.06 and 4.29, 2.63 to
7.02, respectively). There was likewise a strong
associationbetweenfavourablerecommendationsonthe
use of rosiglitazone and financial conflicts of interest
(3.36, 1.94 to 5.83). These links persisted when articles
rather than authors were used as the unit of analysis
(4.69, 2.84 to 7.72), when the analysis was restricted to
opinion articles (6.29, 2.15 to 18.38) or to articles in
which the rosiglitazone controversy was the main focus
(6.50, 2.56 to 16.53), and both in articles published
beforeand afterthe FoodandDrug Administrationissued
asafetywarningforrosiglitazone(3.43,0.99to11.82and
4.95, 2.87 to 8.53, respectively).
Conclusions Disclosure rates for financial conflicts of
interestwereunexpectedlylow,andtherewasaclearand
strong link between the orientation of authors’ expressed
views on the rosiglitazone controversy and their financial
conflicts of interest with pharmaceutical companies.
Although these findings do not necessarily indicate a
causallinkbetweenthepositiontakenonthecardiacrisk
ofrosiglitazoneinpatientswithdiabetesandtheauthors’
financial conflicts of interest, they underscore the need
for further changes in disclosure procedures in order for
the scientific record to be trusted.
INTRODUCTION
The “rosiglitazone controversy” was instigated by a
meta-analysis that showed a significant increase in the
risk of myocardial infarction associated with the use of
the thiazolidinedione drug rosiglitazone in patients
with diabetes.
1 The scientific community responded
with a deluge of letters, commentaries, new systematic
reviews, and meta-analyses in peer-reviewed journals
and in the lay press. These publications presented dif-
fering views on the safety of rosiglitazone use—some
diametrically opposite.
In 1995, a similar highly contested debate came
about after several articles questioned the safety of cal-
cium channel antagonists. In this case, at least part of
thecontroversyappearedtobefuelledorexplainedby
theauthors’financialconflictsofinterestwiththephar-
maceutical industry.
2 Numerous studies have since
confirmed an association between conflicts of interest
and pro-industry conclusions in articles.
3-6
In the past decade, research and policy has focused
on this association, leading to important progress in
policies to manage and encourage disclosure of such
financial conflicts of interest.
7-9 Whether these policies
have made any impact on the association between
financial conflicts of interest and views expressed in
scientific reports is still unknown.
10 Indeed, the extent
to which this association applies to the rosiglitazone
controversy is unclear.
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association between authors’ financial conflicts of
interest and their published views on the risk of myo-
cardial infarction with rosiglitazone use and recom-
mendations on use of rosiglitazone. We sought also to
estimatetheprevalenceoffinancialconflictsofinterest
(defined as the number of studies that have conflicts of
interest divided by the total number of studies). Of
those articles identified as having financial conflicts of
interest, we determined the percentage that appropri-
ately disclosed these relationships.
METHODS
This review followed a predefined protocol, with sen-
sitivity analyses arranged to answer specific questions
that surfaced during study conception. Sensitivity ana-
lyseswerespecifiedapriori;noneofthesensitivityana-
lyses was a post hoc addition.
Article selection
On10April2009,weusedWebofScienceandScopus
to search for potentially eligible articles. Eligible arti-
cles cited the index publications in the rosiglitazone
debate—that is, either the Nissen and Wolski 2007
meta-analysis,
1 which first highlighted the link
between rosiglitazone and cardiovascular events in
patientswithdiabetes,ortheinterimreportoftheRosi-
glitazone Evaluated for Cardiac Outcomes and Regu-
lation of Glycemia in Diabetes (RECORD) trial,
11
which was released to respond to the findings of the
Nissen and Wolski meta-analysis. To be included, stu-
dies had to comment on rosiglitazone and the risk of
myocardial infarction. We included original research,
reviews, meta-analyses, guidelines, responses, letters,
commentaries, and editorials that were not written by
the authors of the index publications. Articles written
in foreign languages were obtained and translated.
Data extraction
Data on financial relationships
Onereviewerextractedforallauthorsofeacharticledata
regarding any indication of financial relationships with
pharmaceuticalcompanies(for example, conflictor dua-
lity of interest statements, employment with a pharma-
ceutical company, contact information). This data was
then blinded (blocked) electronically and irreversibly.
Studies were classified by the nature of the financial
conflictof interest and the type of pharmaceutical com-
pany.Thefinancialconflictsofinterestweredefinedas:
1)norelationship;2)apharmaceuticalcompanyfunded
the article inquestion; 3)the authorwasemployed by a
pharmaceutical company; 4) a pharmaceutical com-
pany funded research other than that covered in the
article in question; or 5) the author was a consultant,
advisory board member, speaker, lecturer, or receives
travelorhonorariafromapharmaceuticalcompany,or
owns stock. The pharmaceutical companies were
divided into: 1) rosiglitazone manufacturer (GlaxoS-
mithKline); 2) pioglitazone manufacturer (Eli Lilly and
Takeda); or 3) manufacturer of antihyperglycaemic
agents other than rosiglitazone or pioglitazone.
Tocompletetheassessmentoffinancialrelations,we
searched for disclosure in all publications within two
years of the original publication of all contributing
authors of each article using Scopus and PubMed.
We also conducted a general internet search for con-
flict of interest using each contributing author’s name
incombinationwithvariouskeywordsinGoogle,such
as “disclosure,”“ conflict of interest,”“ duality of inter-
est,”“ speaker,”“ speaker’s bureau,”“ honoraria,” and
“honorarium.”
Grading authors’ positions
Twoindependentreviewerswithoutfinancialconflicts
of interest graded each article in terms of: 1) the
authors’ position on the association between rosiglita-
zone use and the risk of myocardial infarction; and 2)
recommendations on the continuation or cessation of
rosiglitazone. We used a pre-defined grading system
(table 1) based on the system used by Als-Nielsen and
colleagues,
12 and Stelfox and colleagues’ classification
scale,
2 to grade authors’ enthusiasm for the experi-
mental intervention in the conclusion section of
reports of randomised trials.
Authors were classified as having a favourable view
onrosiglitozone’s safety(that is,rosiglitazone doesnot
increase the risk of myocardial infarction), a neutral
view, or an unfavourable view on the risk of
myocardial infarction with rosiglitazone and on
recommendations on the use of the drug. Strong
recommendations calling for the use of pioglitazone,
the main competitor drug to rosiglitazone, were also
recorded. We did not take into consideration state-
ments regarding the risk of developing congestive
heart failure because this disorder is well established
as an adverse effect of all available glitazones.
Authors who were identified as neutral on risk of
myocardial infarction and favourable or unfavourable
on use were classified as favourable or unfavourable,
respectively. Likewise, authors that were neutral on
use of rosiglitazone and were favourable or unfavour-
able on risk of myocardial infarction were classified as
favourableorunfavourable,respectively.Inthecaseof
multiple contributions by a single author, we treated
thefirstauthorofeacheligiblepaperastheunitofana-
lysis.Authorswithneutralarticleswhohadalsowritten
favourableorunfavourablearticleswereconsideredas
having a favourable or an unfavourable opinion,
respectively. In the case that an author had both a
favourable and an unfavourable opinion, the author
was classified as neutral.
During review of the 404 unique items, the two
reviewers had 41 disagreements, and after discussion
a consensus on each article was reached. A third party
was available for final decision if consensus could not
be reached. Initial kappa with linear weighting
between the two reviewers was 0.83 and 0.85 for the
two classification scales respectively.
Rate ratios and 95% confidence intervals were
calculated as a measure of the strength of association
betweenfinancialconflictsofinterestandviewsonrisk
of myocardial infarction with rosiglitazone.
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We conducted sensitivity analyses to enhance the
validity and robustness of our results. On the basis of
the approach Stelfox and colleagues used in their
investigation of conflicts of interest and the safety of
calciumchannelblockers,
2wecombinedthetwocom-
ponents of the classification scale in table 1 to create
one overall rating per article.
In addition, we tested whether using the articles
(instead of the authors) as units for analysis would
change our conclusions. We also excluded articles
written on other subjects that briefly referenced the
rosiglitazone controversy. Analysis of only opinion
pieces (letters, commentaries, and editorials) was also
done. Given that views on the risk of myocardial
infarction associated with rosiglitazone might have
beenaffectedbytheblackboxsafetywarningthatrosi-
glitazone could be associated with increased cardiac
risk, issued by the Food and Drug Administration on
30July2007,
1314wealsoexploredourfindingsbycon-
sidering articles published before and after this date.
RESULTS
Search and retrieval
Weretrieved847potentiallyeligiblearticles,asjudged
by their citation link to the index publications; evalua-
tion of their content enabled the exclusion of 634 arti-
cles (that is, the articles did not comment on
rosiglitazone and the risk of myocardial infarction or
use of rosiglitazone). We could not obtain the full text
of four articles, which were, therefore, excluded. We
also excluded seven articles written by the authors of
the index articles. Thus, 202 articles were included in
the analyses, including 18 articles that were translated
to English before assessment. After accounting for
multiple contributions from a single author, 180
unique authors were used for analysis. The article
selection process is depicted in the figure. Individual
studies are described in the web extra file.
Prevalence and disclosure of financial conflicts of interest
Ofthe202eligiblestudies(10reportedoriginalresearch,
91 were letters, editorials, or commentaries, and 101
were reviews, meta-analyses, or guidelines), 108 articles
(53%) included a conflict of interest statement (nine of
the 10 (90%) original research articles, 39 of the 91
(43%) letters, editorials, or commentaries, and 60 of the
101 (59%) reviews, meta-analyses, or guidelines).
A total of 90 (45%) of the 202 articles were authored
by individuals who had financial conflicts of interest.
Ofthe90studieswithconflictsofinterest,69(77%)had
astatementdisclosingtheconflictofinterestinthearti-
cleitself.Theother21studieswithfinancialconflictsof
interest (23%) did not disclose these relationships,
which were discovered through searching other publi-
cationsbythesameauthorortheinternet.Three(14%)
of these 21 studies published a statement declaring no
conflicts of interest. Detailed description of included
articles, conflict of interest prevalence, and disclosures
are in the web extra file.
Classification of authors’ positions
In terms of the risk of myocardial infarction associated
with rosiglitazone, 31 (17%) of the 180 unique authors
offered favourable views, 84 (47%) were neutral, and
65 (36%) had unfavourable views about the safety of
rosiglitazone. In terms of recommendations regarding
the use of rosiglitazone, 26 authors had favourable
views (that is, recommended continued use), 116
were neutral, and 38 held unfavourable opinions.
A large proportion of the authors who offered
favourable views about the safety of rosiglitazone had
financialconflictsofinterestwithpharmaceuticalcom-
panies in general (29/31 (94%)), with rosiglitazone
manufacturers (27/31 (87%)), and with pioglitazone
manufacturers (20/31 (65%)), compared with those
authors expressing unfavourable views (18/65 (28%),
13/65 (20%), and 14/65 (22%), respectively). Authors
whohadfavourableviewsonthesafetyofrosiglitazone
weremorethanthreetimesmorelikelytohaveafinan-
cialconflictofinterestwithapharmaceuticalcompany
than were authors who had unfavourable views (rate
ratio 3.38, 95% CI 2.26 to 5.06). There was likewise a
strong association between favourable recommenda-
tions on the use of rosiglitazone and financial conflicts
ofinterest(rateratio3.36,95%CI1.94to5.83;table 2).
The use of pioglitazone
Both the meta-analysis by Nissen and Wolski
1 and the
RECORD trial
11 looked into the cardiovascular safety
of rosiglitazone but not of pioglitazone. The
Table 1 |Classification scale for author position on rosiglitazone safety and its continued use
Risk of myocardial infarction with rosiglitazone Use of rosiglitazone
Favourable
Emphasises that rosiglitazone does not increase the risk
of myocardial infarction Recommendscontinueduseof
rosiglitazone Discredits authors or arguments that emphasise the risk
of myocardial infarction with rosiglitazone
Neutral
Emphasises that there is insufficient evidence to assess
the risk of myocardial infarction with rosiglitazone Makes no recommendation
about drug use
Equitably assesses opposing views
Unfavourable
Emphasises that rosiglitazone increases the risk
of myocardial infarction Recommends use of
alternative drugs or
discontinuing rosiglitazone Criticises authors who discredit concerns about the risk
of myocardial infarction with rosiglitazone
Articles retrieved (n=847)
Unique authors (n=180)
Articles included (n= 202)
Original research (n=10)
Letter, editorial, or commentary (n=91)
Review, meta-analysis, or guideline (n=101)
Articles excluded (n=645)
On the basis of content (n=634)
Could not be obtained (n=4)
Written by authors of index articles (n=7)
The article selection process
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zone may be cardioprotective.
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Authors who had favourable views about the use of
rosiglitazone were more likely to have a financial con-
flict of interest with a manufacturer of pioglitazone
than were authors with unfavourable views (73% (19/
29)v26%(10/44);rateratio3.28,95%CI1.88to5.73).
However, 29 articles overall strongly recommended
using pioglitazone rather than rosiglitazone, 25 (86%)
of which were authored by individuals with financial
conflicts of interest with a pioglitazone manufacturer.
Sensitivity analyses
All sensitivity analyses are presented in part E of the
web extra file. Our results were similar when we per-
formed analyses using Stelfox and colleagues’ com-
bined scale
2: 42 (23%) authors were classified as
having a favourable opinion on the risk of myocardial
infarctionwithrosiglitazone,70(39%)wereneutral,and
68 (38%) had an unfavourable view. One author had
disparate views on the risk of myocardial infarction
and its continued use and was thus classified as neutral.
When we looked at the link between authors’ views on
thesafetyofrosiglitazoneandfinancialconflictsofinter-
est, the results were similar to those in our original ana-
lysis.Atotalof79%(33/42)ofauthorswhoexpresseda
favourable view had financial conflicts of interest with
the manufacturer of rosiglitazone, compared with 22%
(15/68) of authors who expressed an unfavourable opi-
nion (rate ratio 3.65, 95% CI 2.31 to 5.77).
When we used each article as a unit of analysis, we
found that 35 (17%) were favourable, 95 (47%) were
neutral, and 72 (36%) were unfavourable in terms of
risk of myocardial infarction with rosiglitazone. In
total, 86% (30/35) of favourable articles were asso-
ciatedwitha financialconflictofinterestwiththeman-
ufacturer of rosiglitazone, compared with 18% (13/72)
of articles that reported an unfavourable viewpoint
(rate ratio 4.69, 95% CI 2.84 to 7.72).
Whenwerestrictedtheanalysistothe105 articlesin
which the rosiglitazone controversy was the main
focus,wefoundthatarticleswhoseauthorshadfavour-
able views on the risk of myocardial infarction with
rosiglitazone were more likely to have financial con-
flicts of interest with the manufacturer of rosiglitazone
than articles expressing unfavourable views (84% (21/
25)v14%(7/51);rateratio6.00,95%CI2.98to12.10).
Wealsofoundthisrelationwhenweundertookanana-
lysis of recommendations on use: 81% (13/16) of arti-
cles expressing a favourable recommendation had
financial conflicts of interest with the manufacturer of
rosiglitazone, compared with 13% (4/31) of articles
expressing an unfavourable recommendation (rate
ratio 6.50, 95% CI 2.56 to 16.53).
Results were also consistent when the analysis was
restricted to the 92 publications that were a commen-
tary, letter, or editorial: 90% (19/21) of articles expres-
sing a favourable view on the risk of myocardial
infarction with rosiglitazone had financial conflicts of
interest with the manufacturer of rosiglitazone, com-
pared with 14% (5/35) of articles expressing an unfa-
vourable view (rate ratio 6.15, 95% CI 2.71 to 13.99).
Analysis of the authors’ recommendations on rosigli-
tazone use yielded nearly identical numbers (80% (12/
15)v13%(3/23);rateratio6.29,95%CI2.15to18.38).
A total of 27 articles were published before the FDA
issued a black box safety warning for rosiglitazone. Of
these27articles,eight(30%)werefavourable,10(37%)
were neutral, and nine(33%)were unfavourable about
rosiglitazone safety. Of the articles in which authors
expressed favourable views on rosiglitazone safety,
75% (6/8) were associated with financial conflicts of
interest with rosiglitazone manufacturers compared
with 22% (2/9) in which authors had an unfavourable
view (rate ratio 3.43, 95% CI 0.99 to 11.82). Similar
results were obtained for the recommendations on
rosiglitazone use for this subset of articles (75% (3/4)
v 17% (1/6); rate ratio 4.50, 95% CI 0.69 to 29.39).
We then repeated our analysis for articles published
after the FDA warning. We found that 89% (24/27) of
articles in which authors presented favourable views
were associated with financial conflicts of interest
with the rosiglitazone manufacturer compared with
17% (11/63) of articles written by unfavourable
authors. Similar results were obtained for the recom-
mendations on rosiglitazone use for this subset of arti-
cles (84% (21/25) v 24% (9/38); rate ratio 3.75, 95% CI
2.10 to 6.72).
DISCUSSION
Our results show a strong association between authors
withfavourableviewsonthesafetyofrosiglitazoneand
financial conflicts of interest the authors had with the
manufacturer of rosiglitazone, pioglitazone, and with
Table 2 |Author position on rosiglitazone safety and financial conflicts of interest
Risk of myocardial infarction with rosiglitazone Use of rosiglitazone
Favourable
(n=31)
Neutral
(n=84)
Unfavourable
(n=65) Rate ratio (95% CI)*
Favourable
(n=26)
Neutral
(n=116)
Unfavourable
(n=38) Rate ratio (95% CI)*
Any manufacturer 29 (94) 32 (38) 18 (28) 3.38 (2.26 to 5.06) 23 (88) 46 (40) 10 (26) 3.36 (1.94 to 5.83)
Rosiglitazonemanufacturer† 27 (87) 25 (24) 13 (20) 4.29 (2.63 to 7.02) 21 (81) 30 (26) 9 (24) 3.60 (2.00 to 6.48)
Pioglitazone manufacturer† 20 (65) 31 (30) 14 (22) 3.96 (2.45 to 6.39) 19 (73) 30 (26) 10 (26) 3.28 (1.88 to 5.73)
None 2 (6) 52 (62) 47 (72) — 3 (12) 70 (60) 28 (74) —
Values are numbers (percentages) unless otherwise indicated.
*Comparing favourable versus unfavourable views.
†Categories not mutually exclusive.
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Authorswhowereunfavourableontheissueofrosigli-
tazone safety were largely free of identifiable financial
conflicts of interest. Sensitivity analyses demonstrated
that these links persisted when articles rather than
authorswereusedastheunitofanalysis,whentheana-
lysis was restricted to opinion articles or to articles in
which the rosiglitazone controversy was the main
focus, and both in articles published before and after
the FDA issued a safety warning.
Owing to increased demands for transparency, most
majorjournalshaveadisclosurepolicythatincludesnot
only original articles, but also letters, editorials, and
other article types. With requirements for disclosure of
conflicts of interest seemingly ubiquitous in medical
journals, it was surprising to see that only half of the
articlesweanalysedhadcompetinginterestsstatements.
Our findings underscore the need for accountability by
both authors and journals. The rate of disclosure we
foundrepresentsremarkableprogressoverthepastdec-
ade, however, because in 1998 Stelfox and colleagues
reportedthatonly3%ofstudieshadaconflictofinterest
statement.
2 Given the potential influence of financial
conflicts of interest on the views expressed in articles,
the low rate of disclosure by authors of editorials and
commentaries is disappointing.
Strengths and limitations of the study
We used a comprehensive search strategy to identify
articles for our analysis,and reviewed articles in dupli-
cate. This approach was associated with high inter-
observer agreement regarding the classifications of
authors’ financial conflicts of interest and expressed
views and recommendations. We also blinded the
reviewers who classified authors’ positions relative to
the source that funded the research in order to reduce
the risk of bias. Multiple sensitivity analyses were
planned and conducted; the similarity of their results
to those of the primary analyses demonstrates the
robustness of our findings.
The inferences presented in this study are limited,
however, by the observational and descriptive nature
of this evidence. Our analysis was unable to evaluate
the effect of the strength of financial associations (that
is, assign monetary magnitude to the relationships).
Furthermore, the findings rely exclusively on the per-
tinence and reproducibility of the classifications of the
financial conflicts of interest and the positions articu-
lated by the authors.
We were unable to clarify the effect of financial con-
flicts of interest with the manufacturers of rosiglita-
zone’s direct competitor, pioglitazone, because the
majority (82%) of authors who had financial conflicts
of interest with pioglitazone manufacturers also had
financial conflicts of interest with the maker of rosigli-
tazone. This link may explain the apparently counter-
intuitivefindingthatalargeproportionofauthorswith
a favourable view about rosiglitazone’s safety also had
financialconflictsofinterestwithmanufacturersofpio-
glitazone. This again underscores the complexity of
financial conflicts of interest, the extent to which they
affectkeyopinionleaders,andtheshortcomingsofthe
current approach to disclosure.
Only53%ofthearticleshadconflictofintereststate-
ments, thus we relied on exhaustive PubMed, Scopus,
and Google searches to identify unreported financial
conflicts of interest. Given that no formal database
exists for reporting conflicts of interest, our findings
may very well underestimate the prevalence of con-
flicts of interest among authors weighing in on rosigli-
tazone’s safety. We also could not assess the extent to
whichtheobservedassociationreflectsghostwritingin
publications related to rosiglitazone.
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We found many articles that cited the index studies
but did not reference the controversy surrounding the
riskofmyocardialinfarctionwithrosiglitazone;thus,a
number of articles that could have been classified as
neutral were likely excluded. We might have also
missed articles that refer to the effect of rosiglitazone
on the risk of myocardial infarction, either favourably
or unfavourably, without directly citing the index arti-
cles. In addition, original research often has a lag time
associatedwith publication that may lead to bias in the
sensitivity analyses of articles published before the
FDA’s black box warning label and those published
after. Of note, only 10 original research studies were
included in these analyses, which limits the potential
effect of this bias.
Other limitations may be caused by the characteris-
tics of authors. Authors who have favourable views on
rosiglitazone may be more likely to form relationships
withmanufacturersofglitazones.Cardiologistsareless
likely to have an association with glitazone manufac-
turers than are endocrinologists, although cardio-
logists might be more concerned and vocal about the
risk of myocardial infarction with rosiglitazone than
are endocrinologists (who may be more concerned
about rosiglitazone’s effects on glycaemic control).
Conclusions
The disclosure rates of financial conflicts of interest
were unexpectedly low, and there was a clear and
strong link between the orientation of authors’
expressed views on the rosiglitazone controversy and
theexistenceoffinancialconflictsofinterestwithphar-
maceutical companies. These findings, while not
necessarilycausal,underscoretheneedforfurtherpro-
gressinreportinginorderforthescientificrecordtobe
trusted.
In the heat of the rosiglitazone controversy, patients
and clinicians alike were exposed to many arguments
on both sides of the debate. How could interpretation
of the same evidence result in disparate and impas-
sioned positions? We aimed to determine whether
financialconflictsofinterestwithpharmaceuticalman-
ufacturerscouldbefuellingthisfire.Fromourfindings,
it appears that the answer is yes. We realise that key
opinion leaders who report competing financial inter-
ests may not necessarily be biased by these financial
relationships, but our findings indicate a strong asso-
ciation that users of the scientific literature should
recognise.
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stimulatenovelideasthatcanaddresstheissueofmyo-
cardial infarction with rosiglitazone. One method
would be controlling for investigator bias in research
studies as routinely as we control for other biases, with
one report proposing conducting standard conflict of
interestanalysestoseeifreportedfinancialtiesarepre-
dictive of conclusion.
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What is already known on this topic
Recent demands for increased transparency have led to stricter and more prevalent
policies on disclosures of conflicts of interest
Over the past decade, various studies have shown an association in published articles
between conflicts of interest and proindustry conclusions
What this study adds
Despite the ubiquity of requirements for reporting conflicts of interest, the presence of
conflict of interest statements in the articles we assessed was low (53%)
Authors who had favourable views on the safetyof rosiglitazone were more likelyto havea
financial conflict of interest with a pharmaceutical company than were authors who had
unfavourable views
Our findings serve as a call to action for an ongoing conversation on how best to foster
objectivity in readers and writers of the scientific literature
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